Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

RXI adds no value to MirImmune acquisition as there's no money to develop the pipeline. I just don't get it.

And between Pavco leaving and Eliseev, as CBO, apparently not getting bites, I am growing ever more dubious.

The future: Unless an upfront $ deal occurs, the next dilution will wallop shareholders even more as a frugal $10 million equity raise won't even allow for development of the vaunted immuno-oncology drugs. (I know, it's difficult believe but numbers don't lie)